Summary:
This study evaluates a new injectable medication to see if it better treats symptoms of schizophrenia. The purpose of the study is to measure the amount of study medication in your blood when you are administered multiple injections of either the study medication or Invega Sustenna. The overnight stays will take place in our Observation Unit.
Qualified Participants Must:
• Be between the ages of 18 - 65 years old
•
Have a diagnosis of schizophrenia
•
have not received schizophrenia medication as a shot within the last year
•
Are not currently taking Risperdal
Qualified Participants May Receive:
Compensation for every study visit you complete, as well as an end-of-study bonus. Transportation to all study visits is also provided.